Schaut Euch mal HEMOSOL (HMSL, 886290) vorbörslich an!! Hammer!! - 500 Beiträge pro Seite

[gino]

Gruß
gino

[ustrading]

hm, 4Mio. gehandelte Aktien nach knapp 2Stunden ohne irgend eine News. Sollte man mal dran bleiben

[aimster]

schau mal in dein w : o postfach gino
mfg

[bullagainstbear]

Hemosol machte gestern 15 % gut, ohne dass ich irgendwelche Neuigkeiten finden kann. Schlusskurs bei 0,69 USD, Höchstkurs bei 0,89 USD. Weiss jemand mehr ?

[bullagainstbear]

Wie nun, keiner weiss etwas??????????

[spitzohr]

eventuell dieser bericht:


Hemosol Inc. is going back to the drawing board to figure out why its flagship blood substitute product failed in clinical testing earlier this year.

Based on a recommendation of an independent safety review committee, the cash-strapped company said it plans to conduct further animal studies to determine why clinical patients undergoing cardiac bypass surgery with Hemolink had a high incidence of heart damage, forcing the study to end prematurely.

"We believe that we know how to address this issue but need to perform some non-clinical research to confirm our understanding," said Hemosol president and chief executive officer Lee Hartwell.

Hemosol`s vice-president of medical affairs, Michael Shannon, said that while the heart study included a limited number of patients, "there was no apparent difference in mortality or length of hospital stay between the Hemolink group and the control group."

While most industry sources doubt the company will be able to restart clinical tests with heart patients, Hemosol said it still believes Hemolink can be developed into a treatment for some conditions, including anemia caused by chemotherapy in cancer treatments and as a replacement for patients with life-threatening blood loss.

On the Toronto Stock Exchange yesterday, Hemosol shares closed unchanged at 76 cents, compared with a 52-week high of $3.25.

The Mississauga-based biotech company also disclosed that at June 30, it had $909,000 of cash.

Together with the unused portion of a $20-million credit facility, it said it has enough money to continue operating through the end of the year. However, its ability to continue as a going concern beyond the end of the year depends on securing additional financing, it added.

"This is a very difficult time for the company given our limited financial resources," Mr. Hartwell said, adding that Hemosol`s early-stage research and manufacturing plant "will be an attractive package to potential investors and prospective partners."

Hemosol also reported a loss of $9.6-million or 21 cents a share for the second quarter this year, compared with a year-earlier loss of $19.9-million or 47 cents. The reduced deficit resulted from two cost-savings programs and a decision to suspend all clinical trials with Hemolink during a review of the cardiac bypass study.

Mr. Hartwell, who has been interim CEO since the death of his predecessor, John Kennedy, in June, was formally appointed president and CEO.

[schnirchel]

Hemosol Inc.

00:00 EDT Tuesday, August 19, 2003

(HML - TSX)

2Q to June 30
Year ago

Revenue0
0
Net profit(9,624,000)
(19,923,000)
Net profit/share(0.21)
(0.47)
Cash flow(7,656,000)
(14,486,000)
Avg. Shares46,103,000
41,962,000

6 months to June 30 Year ago
Revenue 0 0
Net profit (20,011,000) (31,672,000)
Net profit/share (0.43) (0.75)
Cash flow (15,975,000) (25,347,000)
Avg. Shares 46,103,000 41,955,000

© The Globe and Mail
In dem Bericht hieß es u.a. , das man noch 0,9 Mio Cash und den Rest des 20 Mio $ CD Kredits habe um die Tierversuche fortzusetzen. Wie hoch ist der Rest? Das würde mich schon brennend interessieren.
Der alte Kennedy ist leider an Krebs verstorben.


:O